Earnings Call
Apr 14, 2026
Q1 FY2026
EPS Estimate
2.68
EPS Actual
2.70
Post-Earnings Close
$240.10
Earnings Reaction
+0.9%
Johnson & Johnson opened 2026 with a quarter that substantiates its claim to being the cleanest growth story in large-cap healthcare. Worldwide operational sales reached $24.1 billion, up 6.4% year-over-year, beating the consensus estimate of roughly $23.6 billion, while adjusted diluted EPS of $2.70 cleared the $2.67 estimate. Critically, the headline growth rate understates underlying momentum: STELARA, now in full biosimilar erosion, dragged approximately 540 basis points off total company growth and nearly 920 basis points off Innovative Medicine. Strip that out and the enterprise grew at roughly 16.6% on the Innovative Medicine side alone, with 10 brands delivering double-digit growth. Management responded by raising full-year operational sales guidance to a midpoint of $100.2 billion, the first time JNJ has guided to a $100 billion revenue year, and lifting adjusted operational EPS guidance by $0.02 to an $11.30, $11.50 range, implying roughly 5.7% growth at the midpoint.
Report generated on Apr 14, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full JNJ analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.